Zebutinib ’s product revenue in the United States was $ 720,000.
May 12, Beijing time, BeiGene (BGNE.US/06160.HK) released the first quarter of 2020 financial results. The data shows that Beiji’s revenue in the first quarter was 52.06 million US dollars, compared with 77.83 million US dollars in the same period last year, a year-on-year decrease of 33.1%. One of the reasons for the decrease in quarterly revenue was the lack of cooperation revenue after the termination of the cooperation agreement with Xinji about Baizean. In the reporting period, BeiGene ’s cooperation income was zero, compared with 20.41 million US dollars in the same period last year.
In the first quarter, BeiGene ’s net loss was US $ 364 million, compared with a loss of US $ 168 million in the same period last year.
BeiGene is a biopharmaceutical company focused on the development and commercialization of innovative molecular targeting and immuno-oncology drugs for cancer treatment.
According to BeiGene ’s performance report, as of March 31, 2020, ABRAXANE, Ruifumei and Vidasa ’s sales in China generated 3082 product revenue 10,000 US dollars, a decrease of 46.3% from the 57.42 million US dollars in the same period in 2019, mainly due to the negative impact of the new global pneumonia global pandemic, increased competition for generic drugs, and the National Drug Administration (NMPA) from 2020 3 Started suspending sales of ABRAXANE in China in May.
Bai Zean ’s product revenue since its commercial development in China in March 2020 was $ 20.53 million. Baizean is the first self-developed new anti-cancer drug approved in China after Baekje China’s self-developed BTK inhibitor Zebutinib was approved by the US FDA. In the first quarter, Zebutinib ’s product revenue in the United States was $ 720,000.
Ou Leiqiang, founder, CEO and chairman of BeiGene, said: “ In addition to Baizean, which was successfully listed on the Chinese market this quarter, we will continue to expand the company ’s business portfolio, and it is expected to reach as many as 11 products by the end of next year. “
In the first quarter of 2020, the cost of BeiGene was US $ 426 million, compared with US $ 252 million in the same period last year, of which R & D expenses were US $ 304 million compared with the same period last year It ’s $ 178 million. The increase in R & D expenses was mainly due to ongoing and newly initiated late-stage key clinical trials continued to increase expenses, development costs related to cooperation with Amgen, new drug registration preparations, and costs related to pre-commercial activities and supply .
Monday ’s US stocks closed, and BeiGene reported $ 163.26 per share, up 4.11%, and after the market rose 0.02%. On May 11, Baekje China’s Hong Kong stocks closed at HK $ 93 / share, up 1.64%.